drugset / Trial / NCT04704492
A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis
NaSingle-groupOpen-labelTreatment
Summary
This was an open phase I trial to evaluate the pharmacokinetic, pharmacodynamic, safety and clinical activity profiles of anti-CD22 monoclonal antibody SM03 in patients with active RA.
Timeline
- Start
- 2012-08-14
- Primary completion
- 2013-12-16
- Completion
- 2013-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SM03 | Monoclonal antibody | 600 mg | Intravenous |
| Subject | SM03 | Monoclonal antibody | 900 mg | Intravenous |